Molecular neuro-oncology in clinical practice: a new horizon

Primary brain tumours are heterogeneous in histology, genetics, and outcome. Although WHO's classification of tumours of the CNS has greatly helped to standardise diagnostic criteria worldwide, it does not consider the substantial progress that has been made in the molecular classification of m...

Full description

Saved in:
Bibliographic Details
Main Authors: Weller, Michael (Author) , Pfister, Stefan (Author) , Wick, Wolfgang (Author) , Hegi, Monika E (Author) , Reifenberger, Guido (Author) , Stupp, Roger (Author)
Format: Article (Journal)
Language:English
Published: 26 July 2013
In: The lancet. Oncology
Year: 2013, Volume: 14, Issue: 9, Pages: e370-e379
ISSN:1474-5488
DOI:10.1016/S1470-2045(13)70168-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(13)70168-2
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204513701682
Get full text
Author Notes:Michael Weller, Stefan M Pfister, Wolfgang Wick, Monika E Hegi, Guido Reifenberger, Roger Stupp
Description
Summary:Primary brain tumours are heterogeneous in histology, genetics, and outcome. Although WHO's classification of tumours of the CNS has greatly helped to standardise diagnostic criteria worldwide, it does not consider the substantial progress that has been made in the molecular classification of many brain tumours. Recent practice-changing clinical trials have defined a role for routine assessment of MGMT promoter methylation in glioblastomas in elderly people, and 1p and 19q codeletions in anaplastic oligodendroglial tumours. Moreover, large-scale molecular profiling approaches have identified new mutations in gliomas, affecting IDH1, IDH2, H3F3, ATRX, and CIC, which has allowed subclassification of gliomas into distinct molecular subgroups with characteristic features of age, localisation, and outcome. However, these molecular approaches cannot yet predict patients' benefit from therapeutic interventions. Similarly, transcriptome-based classification of medulloblastoma has delineated four variants that might now be candidate diseases in which to explore novel targeted agents.
Item Description:Gesehen am 02.11.2021
Physical Description:Online Resource
ISSN:1474-5488
DOI:10.1016/S1470-2045(13)70168-2